Abstract 426P
Background
In SELECT, PFS was significantly longer with LEN 24 mg/d (median: 18.3 mos) vs placebo (median: 3.6 mos; HR 0.21, 99% CI: 0.14–0.31) in pts with RR-DTC; however, the dose-reduction rate due to TEAEs was 68%. This study was designed to evaluate if a starting dose of LEN 18 mg/d could maintain efficacy and reduce toxicity in pts with RR-DTC.
Methods
In this double-blind study, pts ≥18 years (N=152) were randomized 1:1 to receive daily oral LEN at a starting dose of 24 mg (n=75) or 18 mg (n=77): ‘LEN24’ and ‘LEN18’ arms, respectively. The primary efficacy endpoint was ORR as of week 24 (ORRwk24). ORRwk24 analysis was based on a noninferiority test on the odds ratio (OR; noninferiority margin of 0.4 on OR scale). Tumors were assessed by investigators per RECIST v1.1. The primary safety endpoint was the rate of TEAEs grade ≥3 as of wk 24.
Results
The ORRwk24 was 57.3% (95% CI: 46.1–68.5) in LEN24 and 40.3% (95% CI: 29.3–51.2) in LEN18. OR (18/24 mg) 0.50 (95% CI: 0.26–0.96) did not meet criteria for noninferiority. Overall ORR was 64.0% (95% CI: 53.1–74.9) in LEN24 and 46.8% (95% CI: 35.6–57.9) in LEN18 (OR [18/24 mg] 0.50, 95% CI: 0.26–0.95). Median PFS was not reached (NR) in LEN24 (95% CI: 22.1–NR) vs 24.4 mos in LEN18 (95% CI: 14.7–NR) (HR: 1.44, 95% CI: 0.76–2.74). As of wk 24, there was a nonclinically relevant difference in the rate of TEAEs grade ≥3 of 4.2% (95% CI: −19.8–11.4 [LEN24, 61.3% of pts; LEN18, 57.1% of pts]). The most common TEAE grade ≥3 (24/18 mg) as of wk 24 was hypertension (25.3%/19.5%). Overall, TEAEs resulted in dose reduction in 69.3% of pts in LEN24 and 59.7% of pts in LEN18; 14.7% of pts in LEN24 and 16.9% of pts in LEN18 had a TEAE that led to discontinuation.
Conclusions
This study did not show noninferiority of LEN 18 mg vs LEN 24 mg based on the ORRwk24 analysis. ORRwk24 for LEN24 (57%) was consistent with that seen by investigator assessment in SELECT (59%). Incidences of grade ≥3 TEAEs through wk 24 were similar between treatment arms, and no new or unexpected safety signals were observed. These data support selection of LEN 24 mg/d as an appropriate starting dose for pts with RR-DTC.
Clinical trial identification
NCT02702388.
Editorial acknowledgement
Medical writing support was provided by Heather A. Mitchell, PhD, of Oxford PharmaGenesis, Newtown, PA and was funded by Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
M.S. Brose: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Bayer; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): Eisai; Advisory/Consultancy, Research grant/Funding (self): Blueprint Medicines; Advisory/Consultancy, Research grant/Funding (self): Loxo; Advisory/Consultancy, Research grant/Funding (self): Novartis; Advisory/Consultancy: Genzyme; Advisory/Consultancy: Bristol-Myers Squibb; Research grant/Funding (self): Roche/Genentech; Research grant/Funding (self): Exelixis. B. Konda: Research grant/Funding (institution): Advanced Accelerator Applications; Research grant/Funding (institution): Eisai; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Xencor; Research grant/Funding (institution): Bristol-Myers Squibb. C. de la Fouchardiere: Honoraria (self): Eisai; Honoraria (self), Non-remunerated activity/ies: Roche; Honoraria (self), Non-remunerated activity/ies: Servier; Honoraria (self), Non-remunerated activity/ies: Amgen; Honoraria (self), Non-remunerated activity/ies: Pierre Fabre Oncologie; Honoraria (self), Non-remunerated activity/ies: Bayer; Honoraria (self), Non-remunerated activity/ies: Bristol-Myers Squibb. B.G.M. Hughes: Advisory/Consultancy: Roche; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Merck Sharp and Dohme; Advisory/Consultancy: Eisai; Advisory/Consultancy: Takeda; Research grant/Funding (self): Amgen. A.G. Gianoukakis: Advisory/Consultancy: Eisai; Advisory/Consultancy: Bayer; Advisory/Consultancy: Loxo-Lilly. I. Romanov: Honoraria (self): Eisai; Honoraria (self): Merck Serono; Honoraria (self): Bristol-Myers Squibb. M.K. Krzyzanowska: Advisory/Consultancy, Research grant/Funding (self): Eisai; Advisory/Consultancy: Bayer; Research grant/Funding (self): Exelixis; Research grant/Funding (self): Ipsen. T. Binder, R. Xie: Full/Part-time employment: Eisai Inc. C. Dutcus: Leadership role, Research grant/Funding (self), Full/Part-time employment: Eisai Inc. M.H. Taylor: Advisory/Consultancy, Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eisai; Advisory/Consultancy: Array BioPharma; Advisory/Consultancy: Loxo; Advisory/Consultancy: Bayer; Advisory/Consultancy: ArQule; Advisory/Consultancy: Blueprint Medicines; Advisory/Consultancy: Novartis; Advisory/Consultancy: Sanofi/Genzyme. All other authors have declared no conflicts of interest.
Resources from the same session
61P - Clinical implication of BRCA mutation in breast cancer with central nervous system metastasis
Presenter: Jwa Hoon Kim
Session: e-Poster Display Session
62P - IGF axis in breast cancer recurrence and metastasis
Presenter: Hajara Akhter
Session: e-Poster Display Session
63P - Butterfly pea (<italic>Clitoria ternatea</italic> Linn.) flower extract prevents MCF-7 HER2-positive breast cancer cell metastasis in-vitro
Presenter: Azzahra Asysyifa
Session: e-Poster Display Session
64P - Pre-treatment absolute white blood cell profile count as metastatic predictive factors in invasive ductal carcinoma breast cancer
Presenter: Wikania I Gede
Session: e-Poster Display Session
65P - The new mouse anti-nNav1.5 monoclonal antibody
Presenter: Nur Aishah Sharudin
Session: e-Poster Display Session
66P - The TILs near solid structures is a potential prognostic factor of distant metastases in the luminal HER2-negative breast cancer
Presenter: Vladimir Alifanov
Session: e-Poster Display Session
73P - Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study
Presenter: Kyaw Thein
Session: e-Poster Display Session
74P - Comprehensive transcriptome analysis of endoplasmic reticulum stress in osteosarcomas
Presenter: Yoshiyuki Suehara
Session: e-Poster Display Session
75P - The evaluation of selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Presenter: Leo Yamada
Session: e-Poster Display Session
76P - Targeted tumour photoImmunotherapy against triple-negative breast cancer therapy
Presenter: Vivek Raju
Session: e-Poster Display Session